Public Company News
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL
SUZHOU, China, and ROCKVILLE, Md., Oct. 15, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has entered into a clinical collaboration ...
2023-10-16 09:23
2643
Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023
HONG KONG, Oct. 14, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, the "Group", HKEX stock code: 0460) is pleased to announce that the "Group" was selected as one of the first echelon of enterprises in The ...
2023-10-14 20:09
3770
MMTEC, INC. TO HOLD ITS 2023 ANNUAL MEETING OF SHAREHOLDERS ON NOVEMBER 10, 2023
HONG KONG, Oct. 13, 2023 /PRNewswire/ -- MMTEC, Inc. (NASDAQ: MTC) ("MMTEC", "we", "our" or the "Company"), aChina-based technology company that provides access to the U.S. financial markets, today announced that it will hold its 2023 annual meeting of shareholders (the "2023 Annual Meeting") at ...
2023-10-14 07:00
5179
Ucommune Announces Extraordinary General Meeting
BEIJING, Oct. 13, 2023 /PRNewswire/ -- Ucommune International Ltd (NASDAQ: UK) ("Ucommune" or the "Company"), a leading agile office space manager and provider inChina, today announced that an extraordinary general meeting of the Company (the "Meeting") will be held at10 A.M. on November 29, 2023...
2023-10-14 05:00
5908
ZK International Group Announces Receipt of Nasdaq Delisting Notification and Will Request Hearing
WENZHOU, China, Oct. 13, 2023 /PRNewswire/ -- ZK International Group Co., Ltd. (Nasdaq: ZKIN) ("ZKIN", "ZK International" or the "Company"), a leading provider of advanced steel products, today announced that onOctober 10, 2023, the Company received notice from the Listing Qualifications Departme...
2023-10-14 05:00
5379
WiMi Developed a Deep Learning-Based Approach to Personalized Video Recommendations
BEIJING, Oct. 13, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it developed a personalized video recommendation system based on deep learning according to the de...
2023-10-13 20:00
3014
GV is Entering a Memorandum with A College for International Education
TORONTO, Oct. 13, 2023 /PRNewswire/ -- Visionary Education Technology Holdings Group Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, startedto accept senior international students on October 10, 2023. ...
2023-10-13 20:00
3696
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, Oct. 13, 2023 /PRNewswire/ -- Acti...
2023-10-13 20:00
3276
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
New data presented on novel orally bioavailable p300-selective degraders showing significant anti-tumor activity in preclinical models of androgen receptor (AR) positive prostate cancer SEOUL, South Korea and KING OF PRUSSIA, Pa., Oct. 12, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global bio...
2023-10-13 09:00
2960
Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment-Naïve Patients with CLL/SLL Approved by the China CDE
ROCKVILLE, Md. and SUZHOU, China, Oct. 12, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of China ...
2023-10-13 08:22
2431
Wiwynn Demonstrates Next-Gen Cooling Solutions and Collaborations for AI Era at OCP Global Summit 2023
SAN JOSE, Calif., Oct. 12, 2023 /PRNewswire/ -- Wiwynn (TWSE:6669), a leading cloud IT infrastructure provider for hyperscale data centers, is set to showcase its latest cooling solutions and collaborations as part of theOpen Compute Project (OCP) Global Summit 2023on October 17-19, 2023, at San ...
2023-10-13 07:00
3641
Navigating Future Profits: Caravelle's New Ship & Proprietary Carbon Reduction Tech Set to Surge Revenue and Profit Margins
SINGAPORE, Oct. 12, 2023 /PRNewswire/ -- Caravelle International Group (Nasdaq: CACO), a trailblazing global ocean technology company, is thrilled to announce the signing of a Bareboat Charter Agreement with Kanda Shipping Co. Ltd. This strategic move is not merely a fleet expansion; it marks the...
2023-10-12 21:50
2435
CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival
SHANGHAI, Oct. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of long-term disease-free survival in th...
2023-10-12 20:50
2486
ALERT: Taoping Contract Revenue Value Jumps Nearly 100% in First Nine Months of 2023
SHENZHEN, China, Oct. 12, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company"), today reported a nearly 100% year-over-year increase in the Company's contract revenue value for its cloud-based product, software and advertising businesses in the first nine months of 2023. The Company en...
2023-10-12 20:30
4024
Akeso Announced The Lancet Oncology Publishes Promising Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)
HONG KONG, Oct. 12, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso") announced that the results of the multicenter, open-label Phase Ib/II clinical trial (COMPASSION-03/AK104-201) for cadonilimab (PD-1/CTLA-4 bispecific antibody), the globally first bispecific IO drug used to treat advanced s...
2023-10-12 20:00
2354
Viomi Technology Co., Ltd Announces New Spokesperson at the New Home Water Solution Products Launch Event
GUANGZHOU, China, Oct. 12, 2023 /PRNewswire/ -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ: VIOT), a leading IoT@Home technology company inChina, today announced that Ms. Xiwei Tian, a well-known actress in China, has become our brand spokesperson at the launch event for our new...
2023-10-12 20:00
3837
WiMi Proposed Data Enhancement for Convolutional Neural Networks
BEIJING, Oct. 12, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it proposed data enhancement for convolutional neural networks (CNN). Data enhancement is a techni...
2023-10-12 20:00
2454
White-label solution differentiators that help organizations stay ahead of the curve
SINGAPORE, Oct. 12, 2023 /PRNewswire/ -- White-labelling is a common strategy employed across various industries to deliver products or services under one company's brand, while the underlying components or solutions are provided by a different entity. It's an approach that allows businesses to l...
2023-10-12 19:15
2678
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192
* HanAll Biopharma and Daewoong Pharmaceutical marked a pivotal step forward in the development of HL192 (ATH-399A) for the potential treatment of Parkinson's Disease in collaboration with NurrOn Pharmaceuticals. * The Phase 1 Study evaluates the safety, tolerability, and pharmacokinetics of ...
2023-10-12 19:00
2426
Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress
SHANGHAI, Oct. 12, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, has unveiled its phase III clinica...
2023-10-12 18:49
2147
Week's Top Stories
Most Reposted
Asia Pacific Travellers Seek Familiarity, Practicality, Flexibility Amid Shifting Global Dynamics: Visa Report
[Picked up by 326 media titles]
2026-06-16 10:00
Visa and Mintoak Join Forces to Bring Merchant SaaS Capabilities to Acquirers Across Asia Pacific
[Picked up by 312 media titles]
2026-06-17 11:00Tamas Szabo on Pepperstone's Competitive Mindset and the Power of F1
[Picked up by 293 media titles]
2026-06-16 17:40
Rediscover the Art of Gathering with the Luxury Group by Marriott International
[Picked up by 292 media titles]
2026-06-16 11:00
Hyundai Card Reopens Korea's Kimchi Bond Market, Expands Funding Portfolio with Dual-Currency USD-CNY Issuance
[Picked up by 292 media titles]
2026-06-18 15:00
Most Read
51Talk Online Education Group Announces First Quarter 2026 Results
2026-06-12 19:00
10184
NYSE Content Update: Fifth Third Bancorp Celebrates Historic Listing Transfer
2026-06-12 21:08
9352
Cheche Group Announces Results of Extraordinary General Meeting
2026-06-12 20:30
7987
Church Leaders Join Mayor Linda Aitken in Prayer for WA's Fastest Growing City
2026-06-12 15:04
7448
